-
Media Release
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
-
Media Release
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis
-
Media Release
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
-
Media Release
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
-
Media Release
Novartis Kisqali® reduced the risk of cancer recurrence while maintaining quality of life in patients diagnosed with early breast cancer
-
Story
Q&A: Addressing unmet needs for people living with PNH, a rare and chronic blood disorder -
Landing Page
Diseases
-
Story
Discover how inflammation could fan the flames of cancer -
Story
Doing the right thing is good business -
Story
Striving to vanquish leukemia -
Story
Take a visual tour of medicines that target RNA -
Story
Novartis and UC Berkeley take on “undruggable” proteins in new collaboration